Hemant Surgical Acquires 66.66% Stake in Lifesenz for ₹19.98 Cr

Hemant Surgical Industries Limited has acquired a 66.66% majority stake in Lifesenz Cancer Research Labs Private Limited for ₹19.98 Crores, making Lifesenz a subsidiary. This strategic move expands Hemant Surgical's healthcare portfolio into the high-growth precision oncology segment. Lifesenz specializes in personalized cancer treatment solutions through advanced ex-vivo chemo-sensitivity analysis. The acquisition aligns with Hemant Surgical's long-term strategy to participate in emerging areas of advanced diagnostics and precision medicine, leveraging Lifesenz's scientific capabilities and existing collaborations. While Lifesenz is currently in a growth phase, the company anticipates future revenue growth and long-term shareholder value creation through scaling operations, strengthening collaborations, and increasing commercialization opportunities.